Nul has raised US$1m in seed funding for its telehealth platform that combines clinical care and prescription medication to help people reduce their alcohol consumption.
The UK healthtech startup, founded by Matus Maar, is building a service that integrates clinical care, prescription medication, digital treatment pathways and behavioural support.
It offers a fully remote subscription programme built around naltrexone, a medicine used to reduce alcohol cravings by targeting the brain’s reward pathways.
The service includes virtual consultations, ongoing clinical support and structured digital guidance based on The Sinclair Method.
Nul said its approach is aimed at people who want to cut down gradually using medication- and therapy-supported reduction methods, rather than treatment models that require immediate or complete abstinence.
Matus Maar, founder and chief executive of Nul, said alcohol reduction remains one of the largest areas in healthcare that has seen relatively limited modernisation.
Maar said: “Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem.
“Nul is about making evidence-based treatment accessible, discreet and compatible with real life.
The company launched a UK test phase in summer 2025 and said it has onboarded more than 120 paying customers, reaching an annualised revenue run rate of more than £300,000 within its first months, driven largely by organic demand and word of mouth.
The seed round was led by dmg ventures and BYVP, with participation from a group of angel investors.
Alongside the round, Nul said it plans to launch a crowdfunding campaign on Republic Europe to allow retail investors to participate.
The funding will support a full UK commercial launch, expansion of its clinical and product teams, scaling customer acquisition and preparation for future international expansion, including the US market.
